ClinicalTrials.gg
CompletedNCT01201577Updated Jun 1, 2011

Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals

A Phase 1 interventional study of Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC) in Quorum Sensing, Prebiotics and Probiotics, sponsored by University of Nottingham. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-01.

Sponsored by University of Nottingham · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Sepsis with a site in United Kingdom — 14 open to participants now, 14 under way, 1 of them phase 3. Sepsis · United Kingdom.

Planned enrollment
38th of 45
40 · median 215
Started
2009
with 1 other
Phase 1
2 of 95
none open now
Registered
14th of 95
by date

Among the 95 studies in Sepsis with a site in United Kingdom, this one is the 38th largest by planned enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 14th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

14 of the 95 studies in Sepsis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Sepsis with a site in United Kingdom, or all of them as a file.
02

Study summary

It has recently been discovered that bacteria are able to communicate using specialised molecules known as Quorum Sensing Signalling Molecules (QSSMs). An accumulation of QSSMs in their surrounding environment allow for the bacteria to quantify the size of colonies. At specific colony sizes the concentration of QSSMs reaches a critical threshold leading to the activation of genes that cause an infection. It is by this mechanism that bacteria within a colony coordinate behaviour to activate infectivity when colony sizes are large enough to withstand defensive measures from the host's immune system. A disruption of quorum sensing may reduce the severity of infection and this has led to the development of inhibitors of quorum sensing as a new strategy in antibacterial therapy.

QSSMs are also thought to facilitate infection by other mechanisms and are able to influence the number and function of a specific type of immune cell known as an 'antigen presenting cell'. These cells are pivotal in allowing the immune system to recognise components of bacteria as foreign and thereby mount the appropriate response. It was found that large numbers of these types of cells underwent programmed cell death (cell suicide) in the presence of QSSMs compared to when QSSMs were absent. This mirrors the situation in blood sampled from patients with severe infections where there is a greater proportion of cell deaths among antigen presenting cells than other types of immune cell.

This study aims to establish in healthy volunteers, the mechanisms by which QSSMs affect immune cells and facilitate the spread of infection. Antibiotic administration in humans can alter the environment of the intestine and can lead to an overgrowth of harmful bacteria to potentially cause an infection. Probiotics supplements can prevent bacterial overgrowth and potentially reduce infective complications. The mechanism, which we aim to clarify, may involve changes in both the production of QSSMs and the function of immune cells.

Hypothesis

  1. Antibiotic use alters gut flora, leading to the appearance in the systemic circulation of bacterial QSSMs and changes in immune function of the host.
  2. Probiotics and/or prebiotics have beneficial effects by preserving the normal resident gut flora, thereby, modulating bacterial QSSMs and preserving the immune function of the host.

Aims

The aims of our study are 2 fold:

  1. Firstly, to study the effect of orally administered antibiotic on QSSMs (in faeces and blood) and on innate and adaptive immunity in healthy humans.
  2. Secondly, to study the effect of orally administered combinations of prebiotic, probiotic and antibiotic on QSSMs (in faeces and blood) and on innate and adaptive immunity in healthy humans.
03

Conditions studied

  • Quorum Sensing
  • Prebiotics
  • Probiotics
  • Sepsis

Browse trials for

Keywords

  • Quorum sensing
  • Prebiotics
  • Probiotics
  • Sepsis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male volunteers
  • Age 18-55 years
  • Willing to participate and able to give
  • Alcohol abstinence during study

Exclusion criteria

Exclusion Criteria:

  • Smokers/substance abusers
  • Individuals with diabetes mellitus
  • Oral/Intravenous
  • Allergy to azithromycin
  • Individuals already taking regular medications/probiotics/nutritional supplements
  • Individuals with chronic disease or currently under investigation
  • Individuals with ≤3 bowel movements/week
  • Individuals with ≥2 bowel movements/day
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Placebo/Probiotic

    Dietary Supplement: Bifidobacterium longum BB536 · Drug: Azithromycin

  • Active comparator
    Placebo/Prebiotic

    Dietary Supplement: Active hexose correlated compound (AHCC) · Drug: Azithromycin

  • Active comparator
    Prebiotic/Probiotic

    Dietary Supplement: Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC) · Drug: Azithromycin

  • Placebo comparator
    Placebo/Placebo

    Dietary Supplement: Corn starch placebo capsule · Drug: Azithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. Serum QSSM level

    Time frame: 14 days

Secondary outcomes

  1. T cell Th1/Th2 ratio

    Time frame: 14 days

07

Study locations

1 site
  • University of Nottingham
    Nottingham, Nottinghamshire NG7 2UH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2010
First posted
Sep 14, 2010
Start
Oct 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Jun 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01201577
First posted
Sep 14, 2010
Start date
Oct 2009
Primary completion
May 2011
Completion
May 2011
Last update
Jun 1, 2011

Study contacts

Abeed Chowdhury, MB ChB BSc MRCS
principal investigator · University of Nottingham
Dileep Lobo, MBBS DM FRCS
study director · University of Nottingham

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Active Hexose Correlated Compound

Start the discussion